Inhibitory effect of myricetin on the metastasis of human renal cell carcinoma
-
摘要: 目的 研究杨梅酮体内外对人肾癌ACHN细胞株转移的影响。 方法 体外实验应用不同浓度的杨梅酮（25、50、100 μmol/L）刺激ACHN细胞后，采用CCK-8实验、划痕实验和Transwell实验检测杨梅酮对于细胞活力、迁移和侵袭能力的影响。体内实验，首先通过尾静脉注射ACHN细胞建立肾癌肺转移模型，然后通过腹腔注射杨梅酮（15 mg/kg），6周后观察肾癌肺微转移灶评估杨梅酮对肾癌转移的影响。 结果 CCK-8实验显示，与对照组相比，当杨梅酮浓度达到50 μmol/L作用24 h后，能够显著降低细胞活性（P=0.019），并且随着药物浓度增加或作用时间延长抑制效应会更加显著。划痕实验和Transwell侵袭实验显示杨梅酮能显著抑制ACHN细胞的迁移和侵袭能力，并呈药物浓度依赖特性。体内实验也证实，与对照组相比，腹腔注射杨梅酮可显著减少肾癌肺微转移灶的数目。 结论 杨梅酮能够有效地抑制肾癌ACHN细胞的活力、迁移和侵袭能力，具有潜在的应用于肾癌治疗的价值。Abstract: Objective To evaluate the role of myricetin in the metastasis of human renal cancer ACHN cells both in vitro and in vivo. Methods With different concentration of myricetin (25, 50, 100 μmol/L) acting on ACHN cells, the cell viability, migration and invasion were respectively measured with CCK-8 assay, wound healing migration assay and Transwell invasion assay in vitro. A lung metastatic model for human renal cell carcinoma was developed by tail vein injection with ACHN cells. The effect of myricetin on the metastasis of renal cell carcinoma was explored by intraperitoneal injection of myricetin in vivo. After 6 weeks, the micro metastases of the lungs in nude mice was examined. Results Compared to the control group, CCK-8 assay showed that the cell viability was significantly lower in the myricetin group at the concentration of 50 μmol/L for 24 h (P=0.019). The inhibitory effect became more significant with the increase in drug concentration or action time. In addition, myricetin also inhibits the migration and invasion of ACHN cells in a dose dependent manner. Intraperitoneal injection of myricetin significantly reduced the number of the micro metastases of renal cell carcinoma in the lungs of nude mice. Conclusion Myricetin effectively inhibits the cell viability, migration and invasion of human renal cancer ACHN cells. It has the potential therapeutic value in the treatment of renal cell carcinoma.
-
Key words:
- renal cell carcinoma /
- myricetin /
- migration /
- invasion
-
[1] 惠丽娜, 范开席, 徐忠法. 肾细胞癌的治疗方法及应用现状[J]. 山东医药, 2015, 55(14): 102-103. [2] Novara G, Ficarra V, Antonelli A, et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?[J]. Eur Urol, 2010, 58(4): 588-595. [3] Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review[J]. Cancer Treat Rev, 2008, 34(3): 193-205. [4] 刘 磊. 转移性肾细胞癌靶向药物治疗的现状[J]. 国际泌尿系统杂志, 2015, 35(6): 923-926. [5] 吴少花, 陈 君, 刘亚萌, 等. 杨梅素抗肿瘤活性研究进展[J]. 吉林医药学院学报, 2015, 36(5): 381-383. [6] 刘雪丽, 周学锋, 王君瑜, 等. 中药抗肿瘤作用机制研究进展[J]. 中国药师, 2016, 19(6): 1158-1162. [7] Feng J, Chen X, Wang Y, et al. Myricetin inhibits proliferation and induces apoptosis and cell cycle arrest in gastric cancer cells[J]. Mol Cell Biochem, 2015, 408(1-2): 163-170. [8] Huang H, Chen AY, Ye X, et al. Myricetin inhibits proliferation of cisplatin-resistant cancer cells through a p53-dependent apoptotic pathway[J]. Int J Oncol, 2015, 47(4): 1494-1502. [9] Sun F, Zheng XY, Ye J, et al. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo[J]. Nutr Cancer, 2012, 64(4): 599-606. [10] Seydi E, Rasekh HR, Salimi A, et al. Myricetin selectively induces apoptosis on cancerous hepatocytes by directly targeting their mitochondria[J]. Basic Clin Pharmacol Toxicol, 2016, 119(3): 249-258. [11] 郭海清, 任 锋, 陈亚利, 等. 杨梅素对HepG2细胞凋亡的影响[J]. 北京医学, 2014, 36(9): 748-751,799. [12] 李有富, 李魏林. 杨梅素对肝癌细胞Bel-7402裸鼠移植瘤的抑制作用[J]. 中国医药导报, 2015, 12(31): 44-47. [13] 李有富, 李 辉, 韩 涛, 等. 杨梅素诱导人宫颈癌HeLa细胞凋亡及凋亡通路的研究[J]. 西北药学杂志, 2016, 31(3): 270-274. [14] 刘师兵, 陈 君, 吴少花, 等. 杨梅素诱导HeLa细胞凋亡的形态学研究[J]. 吉林医药学院学报, 2015, 36(6): 418-421. [15] Shih YW, Wu PF, Lee YC, et al. Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway[J]. J Agric Food Chem, 2009, 57(9): 3490-3499. -
点击查看大图
计量
- 文章访问数: 3077
- HTML全文浏览量: 266
- PDF下载量: 726
- 被引次数: 0
下载:
